Crinetics Pharmaceuticals Inc (CRNX) fair value: what the stock is really worth
As of Sep 1, 2026: fair value of Crinetics Pharmaceuticals Inc $8.53, price $84.95, upside -90.0%, quality 18 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Crinetics Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $15.31 – $84.95 · fair‑value band $5.63 – $10.66 · the $84.95 price screens above the $8.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Crinetics Pharmaceuticals in your weekly email
Every Wednesday you see whether Crinetics Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Show more
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Stock analysis
Crinetics Pharmaceuticals Inc (CRNX) currently trades at $84.95, while our model-based Fair Value estimate is $8.53, 90.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $5.63 (bear) to $10.66 (bull), the price of $84.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 18/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Crinetics Pharmaceuticals Inc reported revenue of $7.7M in FY2025 versus $1.1M in FY2021, a compound +63.5%/yr. Reported net income was −$465M in FY2025.
Key figures
Market cap $9.0B · EPS (TTM) $−5.06 · Return on equity −42.5% · Return on assets (EBIT) −36.5% · Operating margin −527% · Revenue growth (YoY) +23.4% · Free cash flow −$384M · Net cash $53.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 161% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −90%, CRNX screens richer than that median.
Fair Value models
Bear $5.63Fair Value $8.53Bull $10.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
’16
’17
’18
’19
’21
’22
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−105,567.6% (2020) → −6,714.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Crinetics Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 626 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−90.0% · Bottom 25%
Profitability
Return on assets−26.3% · Below median
Growth and dividend
Revenue growth23.4% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B9.04× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Crinetics Pharmaceuticals Inc (CRNX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $8.53 versus the last price from Sep 1, 2026 of $84.95, about −90% upside (overvalued).
What is the fair value of CRNX?
Our model-based fair value for Crinetics Pharmaceuticals Inc is $8.53 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 1, 2026): $84.95.
What is the quality score of CRNX?
Crinetics Pharmaceuticals Inc has a Quality Score of 18/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crinetics Pharmaceuticals Inc (CRNX)?
Our model-based price target is the fair value of $8.53 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $5.63, optimistic scenario $10.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Crinetics Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $8.53, about −90% upside versus the last price from Sep 1, 2026 of $84.95 (overvalued). Cautious scenario $5.63, optimistic scenario $10.66. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Crinetics Pharmaceuticals Inc (CRNX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crinetics Pharmaceuticals Inc it is $8.53 per share (as of Sep 23, 2026), against a price of $84.95. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Crinetics Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CRNX trades above its calculated fair value: price $84.95, fair value $8.53, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRNX?
No. The price is what the market pays today ($84.95); the fair value is what the company's own numbers justify ($8.53). For Crinetics Pharmaceuticals Inc the two are $76.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Crinetics Pharmaceuticals Inc worth?
The market values Crinetics Pharmaceuticals Inc at about $9.0B (market capitalisation, as of Sep 23, 2026). Per share that is $84.95; our models calculate a fair value of $8.53 per share.
What do the bullish and bearish scenarios say about CRNX?
Our models span a range for Crinetics Pharmaceuticals Inc: cautious scenario $5.63, base $8.53, optimistic $10.66 per share (as of Sep 23, 2026, price $84.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Crinetics Pharmaceuticals Inc (CRNX)?
Balance-sheet figures for Crinetics Pharmaceuticals Inc (as of Sep 23, 2026): return on equity −42.5%. They feed the Quality Score of 18/100, which measures business quality independently of the share price.
How far is CRNX from its 52-week high?
Crinetics Pharmaceuticals Inc trades at $84.95, at its 52-week high of $84.95 and 161% above the low of $32.61 (as of Sep 1, 2026). Distance from the high says nothing about value: that is what the fair value of $8.53 is for.
Which stocks are comparable to Crinetics Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crinetics Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $84.95, calculated fair value $8.53 (−90%), Quality Score 18/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRNX calculated?
We run Crinetics Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Crinetics Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crinetics Pharmaceuticals Inc (CRNX)?
The latest price we hold is from Sep 1, 2026 and stands at $84.95. Our model-based fair value is $8.53, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crinetics Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($10.66). The favourable scenario is already priced in. Weak quality (18/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($5.63 to $10.66) leaves room in how you read the outcome.
Key figures of Crinetics Pharmaceuticals Inc
How large is the market capitalisation of Crinetics Pharmaceuticals Inc (CRNX)?
The market capitalisation of Crinetics Pharmaceuticals Inc is $9.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Crinetics Pharmaceuticals Inc (CRNX)?
Earnings per share at Crinetics Pharmaceuticals Inc are $−5.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Crinetics Pharmaceuticals Inc (CRNX)?
The return on equity (ROE) of Crinetics Pharmaceuticals Inc is −42.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crinetics Pharmaceuticals Inc (CRNX)?
On an EBIT basis the return on assets of Crinetics Pharmaceuticals Inc is −36.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crinetics Pharmaceuticals Inc (CRNX)?
The operating margin of Crinetics Pharmaceuticals Inc is −527% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crinetics Pharmaceuticals Inc (CRNX)?
Revenue at Crinetics Pharmaceuticals Inc is growing +23.4% versus a year earlier (3y avg +17.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Crinetics Pharmaceuticals Inc (CRNX) generate?
The free cash flow of Crinetics Pharmaceuticals Inc is −$384M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Crinetics Pharmaceuticals Inc (CRNX) hold?
Crinetics Pharmaceuticals Inc holds more cash than debt, $53.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Crinetics Pharmaceuticals Inc in the live analysis
One click puts Crinetics Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026